Q3 2022 Nykode Therapeutics ASA Earnings Call Transcript
Greetings, and welcome to the Nykode Therapeutics' third-quarter 2022 financial results call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the call over to Chief Executive Officer, Michael Engsig. Thank you. You may begin.
Thank you very much. And also from our side, a warm welcome to all participants joining here, both from Europe and the early birds from the US. I'll start out with a quick note on the forward-looking statements. We assume you're all familiar with that. So on that note, we'll move forward. With me today here at this third-quarter call, I'm very pleased to have Agnete Fredriksen, our Co-Founder and Chief Business Officer; as well as Harald Gurvin, our Chief Financial Officer. I'm Michael Engsig, CEO of Nykode.
A quick introduction to those of you who are new to Nykode: Nykode is a Norwegian-based immunotherapy company. We're entirely focused to building the leading immunotherapy company. And we're focused, too, on our dual strategy,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |